# Study of ZG005 in Combination With Gecacitinib in Participants With Advanced Cervical Cancer

Source: https://onco.cc/trials/nct07080216/  
OnCo record `nct07080216` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 1/2 trial of Bevacizumab in cervical cancer, run by Suzhou Zelgen Biopharmaceuticals Co.,Ltd, now recruiting.

## Summary

Study of ZG005 in Combination With Gecacitinib in Participants With Advanced Cervical Cancer is a phase 1/2 interventional study registered as NCT07080216 by Suzhou Zelgen Biopharmaceuticals Co.,Ltd, with 120 participants planned, started 2025-09-23 and due to reach its primary completion in 2027-08. Interventions recorded: ZG005, Gecacitinib, Bevacizumab. Conditions listed: Cervical Cancer. No results are recorded here; the registry entry is the source.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-16
- Tags: ctgov-ingest
- Registry id: NCT07080216
- Phase: 1/2
- Setting: A Multicenter, Open-label, Dose-finding and Dose-expansion Phase I/II Study of ZG005 in Combination With Gecacitinib in Participants With Advanced Cervical Cancer
- Sponsor: Suzhou Zelgen Biopharmaceuticals Co.,Ltd
- Enrolled: 120

## Sources

- ClinicalTrials.gov NCT07080216: https://clinicaltrials.gov/study/NCT07080216

## Connected records

- cancers: [Cervical cancer](https://onco.cc/cancers/cervical/)
- drugs: [Bevacizumab](https://onco.cc/drugs/bevacizumab/), [Gecacitinib](https://onco.cc/drugs/gecacitinib/)
- companies: [Suzhou Zelgen Biopharmaceuticals](https://onco.cc/companies/zelgen/)

---
JSON: https://onco.cc/api/v1/entities/nct07080216.json